News Contact Us

India readies 5 sites for Phase 3 Oxford-AstraZeneca vaccine trial

Author : Saipriya Iyer | Published Date : 2020-07-29 

Phase 3 or late-stage clinical trial of the Oxford-AstraZeneca coronavirus vaccine is reportedly set to be conducted across 5 sites in India.

Additionally, Oxford and its partner, AstraZeneca, have chosen the Serum Institute of India to manufacture the COVID-19 vaccine, following the anticipated achievement of positive trial results. The data from the Phase 1 and 2 trials has already been published earlier in July.

As per reports, the DBT (Department of Biotechnology) plays a key role in vaccine development, including funding, facilitating regulatory clearances, and providing access to various networks in the country. Moreover, the Serum Institute of India (SSI) based in Pune has sought permission from the DCGI (Drugs Controller General of India) to conduct the Phase 2 and 3 clinical trials. The institute is planning to commence the manufacturing process of the potential vaccine prior to achieving the final results, in order to ensure wide availability with sizable volumes once it receives overall approvals.

Earlier on 20th July, scientists announced high safety and efficacy of the vaccine developed by the Oxford University, as it induced a strong immune response in the Phase 1 trial. The doses of the vaccine were offered to 1,077 healthy subjects between 18-55 years of age, at 5 hospitals in the UK.

According to the results from this 1st phase, the vaccine candidate has induced a strong antibody as well as T-cell immune responses for over 56 days. The T-cells can significantly safeguard people against the virus for several years. Scientists also have discovered that the immune response could be higher after the patient receives the 2nd dose.

The Phase 1 vaccine trial was conducted among a small group of people to examine its safety as well as the stimulation of the immune system. In the 2nd phase, children and the elderly were studied to evaluate its safety and immunogenicity. The vaccine was then administered to a large number of subjects in the 3rd phase.

Source credit:


About Author

Saipriya Iyer

Saipriya Iyer

Saipriya Iyer presently works as a content developer for fractovia.org. Having dabbled with the domain of content creation for nearly half a decade, she now boasts of an enviable portfolio, holding substantial experience in penning down pieces related to technology, finance, and a wide spectrum of other industry verticals. A qualified computer engineering graduate from the University of Pune, Saipriya can often be found leveraging her knowledge of software technology and electronics in her write-ups. She can be contacted at- [email protected] | https://twitter.com/saipriya_i

Related News

Adobe plans new hiring spree as the company hits record revenues

Published Date: 2020-09-17         Author: Saipriya Iyer

As the COVID-19 pandemic continues to impact the global business landscape, software companies and tech firms seem to be faring much better than other enterprises owing to their compatibility with the work-from-home trend, which ensures employee safety and smooth working of the organization. With ot... Read More

UK housing industry at its four year high according to estate agents

Published Date: 2020-09-11         Author: Saipriya Iyer

Stamp duty cuts and an upsurge in the demand for homes having gardens during the pandemic, has reportedly fueled the housing industry to its highest in the past four years, as per the estate agents and surveyors. Over 44% members of RICS’ (Royal Institute of Chartered Surveyors) have regist... Read More

Sydney share-trading firm Superhero secures over $8 million in capital

Published Date: 2020-09-07         Author: Saipriya Iyer

Superhero, an emerging Sydney-based share trading startup, has reportedly made its entry into the market with over $8 million in capital secured from some of Australia’s largest tech firms. The $8 million investment round was led by the chief and founder of BNPL fintech firm, Zip, Larry Dia... Read More

© 2020 Fractovia. All Rights Reserved